PMID- 16961786
OWN - NLM
STAT- MEDLINE
DCOM- 20061121
LR  - 20181201
IS  - 0333-1024 (Print)
IS  - 0333-1024 (Linking)
VI  - 26
IP  - 10
DP  - 2006 Oct
TI  - Zonisamide for migraine prophylaxis in refractory patients.
PG  - 1199-202
AB  - Zonisamide is a new antiepileptic drug with multiple mechanisms of action and a 
      favourable pharmacokinetic profile. Preliminary data suggest that zonisamide may 
      be effective in migraine prophylaxis. We evaluated the efficacy and tolerability 
      of zonisamide for migraine prophylaxis in refractory patients. We reviewed the 
      charts of adult patients with International Headache Society-defined episodic 
      migraine (EM) or with transformed migraine (TM) according to the 
      Silberstein-Lipton criteria, who had been treated with zonisamide at our 
      out-patient clinic for at least 60 days. Demographic data, zonisamide dosage and 
      duration of treatment were collected and analysed. Headache frequency, attack 
      duration, headache severity and headache-related disability before and after 
      treatment initiation with zonisamide were compared. Thirty-three patients were 
      included in the study (average age 43.9 +/- 8.4 years; 23 (70%) with TM and 10 
      (30%) with EM). The patients had failed an average of 6.2 migraine prophylactic 
      drugs prior to zonisamide. The average zonisamide daily dose was 337.9 +/- 146.3 
      mg and the average duration of treatment was 186.4 +/- 174.0 days. The average 
      number of days with headache per month was reduced in the entire study population 
      from 20.7 +/- 9.5 before zonisamide treatment to 18.0 +/- 11.3 after its 
      initiation (P = 0.06) [in TM from 24.7 +/- 7.3 to 21.0 +/- 10.7 (P = 0.06); in EM 
      from 11.6 +/- 7.6 to 11.0 +/- 9.7 (P = NS)]. No significant changes in other 
      headache parameters were found. Fourteen patients (42.4%) reported adverse events 
      (AEs), the most common of which was fatigue. Most patients (12/14, 85.7%) rated 
      AEs as mild or moderate. In this group of refractory migraine patients, 
      zonisamide therapy did not result in a statistically significant beneficial 
      effect on headache or on associated symptoms.
FAU - Ashkenazi, A
AU  - Ashkenazi A
AD  - Jefferson Headache Center, Philadelphia, PA 19107, USA. 
      avi.ashkenazi@jefferson.edu
FAU - Benlifer, A
AU  - Benlifer A
FAU - Korenblit, J
AU  - Korenblit J
FAU - Silberstein, S D
AU  - Silberstein SD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Cephalalgia
JT  - Cephalalgia : an international journal of headache
JID - 8200710
RN  - 0 (Anticonvulsants)
RN  - 0 (Isoxazoles)
RN  - 459384H98V (Zonisamide)
SB  - IM
MH  - Adult
MH  - Anticonvulsants/*administration & dosage/adverse effects
MH  - Drug Resistance
MH  - Female
MH  - Humans
MH  - Isoxazoles/*administration & dosage/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy/*prevention & control
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Zonisamide
EDAT- 2006/09/12 09:00
MHDA- 2006/12/09 09:00
CRDT- 2006/09/12 09:00
PHST- 2006/09/12 09:00 [pubmed]
PHST- 2006/12/09 09:00 [medline]
PHST- 2006/09/12 09:00 [entrez]
AID - CHA1191 [pii]
AID - 10.1111/j.1468-2982.2006.01191.x [doi]
PST - ppublish
SO  - Cephalalgia. 2006 Oct;26(10):1199-202. doi: 10.1111/j.1468-2982.2006.01191.x.